FY2024 EPS Estimates for Amarin Co. plc Raised by Zacks Research (NASDAQ:AMRN)

Amarin Co. plc (NASDAQ:AMRN - Free Report) - Equities researchers at Zacks Research increased their FY2024 earnings estimates for shares of Amarin in a research note issued on Wednesday, May 22nd. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will earn ($0.16) per share for the year, up from their prior forecast of ($0.17). The consensus estimate for Amarin's current full-year earnings is ($0.19) per share. Zacks Research also issued estimates for Amarin's Q1 2025 earnings at ($0.05) EPS, Q4 2025 earnings at ($0.04) EPS and FY2025 earnings at ($0.21) EPS.

Amarin (NASDAQ:AMRN - Get Free Report) last posted its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.02) EPS for the quarter, beating analysts' consensus estimates of ($0.04) by $0.02. The company had revenue of $56.52 million during the quarter, compared to analysts' expectations of $51.34 million. Amarin had a negative net margin of 18.96% and a negative return on equity of 9.48%. During the same quarter in the prior year, the company posted ($0.04) earnings per share.

Amarin Price Performance

Shares of NASDAQ:AMRN remained flat at $0.85 during midday trading on Friday. 883,286 shares of the stock were exchanged, compared to its average volume of 1,772,380. The firm has a market capitalization of $348.04 million, a price-to-earnings ratio of -7.06 and a beta of 1.96. Amarin has a 1 year low of $0.65 and a 1 year high of $1.49. The firm has a fifty day moving average price of $0.91 and a two-hundred day moving average price of $0.95.

Institutional Trading of Amarin

Several institutional investors have recently modified their holdings of the stock. Significant Wealth Partners LLC lifted its stake in shares of Amarin by 128.7% in the first quarter. Significant Wealth Partners LLC now owns 34,582 shares of the biopharmaceutical company's stock worth $31,000 after buying an additional 19,461 shares in the last quarter. Newbridge Financial Services Group Inc. acquired a new position in Amarin during the 1st quarter worth approximately $37,000. China Universal Asset Management Co. Ltd. grew its holdings in Amarin by 351.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 44,599 shares of the biopharmaceutical company's stock worth $39,000 after acquiring an additional 34,725 shares in the last quarter. Vanguard Personalized Indexing Management LLC lifted its position in shares of Amarin by 100.6% during the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 46,480 shares of the biopharmaceutical company's stock worth $40,000 after buying an additional 23,313 shares during the last quarter. Finally, SVB Wealth LLC lifted its position in shares of Amarin by 100.0% during the 4th quarter. SVB Wealth LLC now owns 60,000 shares of the biopharmaceutical company's stock worth $52,000 after buying an additional 30,000 shares during the last quarter. Institutional investors and hedge funds own 22.25% of the company's stock.

Amarin Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.